vTv Therapeutics’ (VTVT) “Buy” Rating Reaffirmed at BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports. They presently have a $57.00 target price on the biotechnology company’s stock. BTIG Research’s target price would suggest a potential upside of 107.12% from the stock’s current price.

Several other brokerages also recently commented on VTVT. Zacks Research upgraded shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. HC Wainwright reduced their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Rodman & Renshaw began coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 target price on the stock. Finally, Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.83.

vTv Therapeutics Stock Down 2.5%

vTv Therapeutics stock traded down $0.71 on Wednesday, hitting $27.52. The company’s stock had a trading volume of 20,139 shares, compared to its average volume of 53,526. The firm has a market cap of $108.43 million, a P/E ratio of -25.96 and a beta of 0.21. The company has a fifty day moving average price of $31.90 and a 200-day moving average price of $33.55. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.